Egyptian International Pharmaceutical Industries Company

CASE:PHAR Stock Report

Market Cap: ج.م6.6b

Egyptian International Pharmaceutical Industries Valuation

Is PHAR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of PHAR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PHAR (EGP44.11) is trading above our estimate of fair value (EGP6.75)

Significantly Below Fair Value: PHAR is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for PHAR?

Key metric: As PHAR is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for PHAR. This is calculated by dividing PHAR's market cap by their current earnings.
What is PHAR's PE Ratio?
PE Ratio5.6x
Earningsج.م1.16b
Market Capج.م6.56b

Price to Earnings Ratio vs Peers

How does PHAR's PE Ratio compare to its peers?

The above table shows the PE ratio for PHAR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average15.6x
RMDA Tenth of Ramadan for Pharmaceutical Industries and Diagnostic Reagents (Rameda)E
19.3x30.7%ج.م5.1b
BIOC GlaxoSmithKlineE
26.3xn/aج.م3.1b
AXPH Alexandria For Pharmaceuticals & Chemical Industries
7.4xn/aج.م1.6b
OCPH October PharmaE
9.7xn/aج.م1.3b
PHAR Egyptian International Pharmaceutical Industries
5.6xn/aج.م6.6b

Price-To-Earnings vs Peers: PHAR is good value based on its Price-To-Earnings Ratio (5.6x) compared to the peer average (15.6x).


Price to Earnings Ratio vs Industry

How does PHAR's PE Ratio compare vs other companies in the African Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
PHAR 5.6xIndustry Avg. 12.6xNo. of Companies4PE01020304050+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: PHAR is good value based on its Price-To-Earnings Ratio (5.6x) compared to the African Pharmaceuticals industry average (12.6x).


Price to Earnings Ratio vs Fair Ratio

What is PHAR's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PHAR PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio5.6x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate PHAR's Price-To-Earnings Fair Ratio for valuation analysis.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst PHAR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentج.م44.11
ج.م77.62
+76.0%
14.2%ج.م90.00ج.م63.25n/a3
Dec ’25ج.م45.53
ج.م77.62
+70.5%
14.2%ج.م90.00ج.م63.25n/a3
Nov ’25ج.م47.97
ج.م63.13
+31.6%
27.8%ج.م79.60ج.م38.79n/a3
Oct ’25ج.م49.50
ج.م63.13
+27.5%
27.8%ج.م79.60ج.م38.79n/a3
Sep ’25ج.م40.99
ج.م63.13
+54.0%
27.8%ج.م79.60ج.م38.79n/a3
Aug ’25ج.م38.81
ج.م75.30
+94.0%
5.7%ج.م79.60ج.م71.00n/a2
Jul ’25ج.م41.36
ج.م75.30
+82.1%
5.7%ج.م79.60ج.م71.00n/a2
Jun ’25ج.م38.01
ج.م75.30
+98.1%
5.7%ج.م79.60ج.م71.00n/a2
May ’25ج.م35.00
ج.م72.20
+106.3%
7.8%ج.م79.60ج.م66.00n/a3
Apr ’25ج.م44.14
ج.م72.20
+63.6%
7.8%ج.م79.60ج.م66.00n/a3
Mar ’25ج.م48.00
ج.م72.20
+50.4%
7.8%ج.م79.60ج.م66.00n/a3
Feb ’25ج.م40.98
ج.م61.87
+51.0%
26.6%ج.م79.60ج.م40.00n/a3
Jan ’25ج.م36.50
ج.م61.87
+69.5%
26.6%ج.م79.60ج.م40.00n/a3
Dec ’24ج.م40.48
ج.م61.87
+52.8%
26.6%ج.م79.60ج.م40.00ج.م45.533
Nov ’24ج.م38.60
ج.م61.87
+60.3%
26.6%ج.م79.60ج.م40.00ج.م47.973
Oct ’24ج.م33.91
ج.م58.90
+73.7%
25.7%ج.م79.60ج.م40.00ج.م49.504
Sep ’24ج.م31.79
ج.م58.90
+85.3%
25.7%ج.م79.60ج.م40.00ج.م40.994
Aug ’24ج.م25.99
ج.م60.53
+132.9%
22.3%ج.م79.60ج.م50.00ج.م38.813
Jul ’24ج.م27.00
ج.م60.53
+124.2%
22.3%ج.م79.60ج.م50.00ج.م41.363
Jun ’24ج.م26.11
ج.م60.53
+131.8%
22.3%ج.م79.60ج.م50.00ج.م38.013
May ’24ج.م33.48
ج.م60.53
+80.8%
22.3%ج.م79.60ج.م50.00ج.م35.003
Apr ’24ج.م33.65
ج.م60.53
+79.9%
22.3%ج.م79.60ج.م50.00ج.م44.143
Mar ’24ج.م35.18
ج.م65.80
+87.0%
21.0%ج.م79.60ج.م52.00ج.م48.002
Feb ’24ج.م38.47
ج.م65.80
+71.0%
21.0%ج.م79.60ج.م52.00ج.م40.982
Jan ’24ج.م36.51
ج.م63.87
+74.9%
18.2%ج.م79.60ج.م52.00ج.م36.503
Dec ’23ج.م34.45
ج.م63.87
+85.4%
18.2%ج.م79.60ج.م52.00ج.م40.483

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 00:58
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Egyptian International Pharmaceutical Industries Company is covered by 11 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aly AdelBeltone Financial
Michel SaidCI Capital Research
Ahmed MoatazEFG-Hermes Research